Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Paraproteinaemia
ADR ID BADD_A05868
ADR Hierarchy
01      Blood and lymphatic system disorders
01.14      Plasma cell neoplasms
01.14.01      Plasma cell neoplasms NEC
01.14.01.001      Paraproteinaemia
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.23      Plasma cell neoplasms
16.23.01      Plasma cell neoplasms NEC
16.23.01.001      Paraproteinaemia
Description A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin. [MeSH]
MedDRA Code 10061333
MeSH ID D010265
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Monoclonal paraproteinaemia | Monoclonal paraproteinemia | Other paraproteinaemias | Other paraproteinemias | Paraproteinaemia NOS | Paraproteinemia | Plasma cell dyscrasia | Paraproteinaemia | Paraproteinemias | Paraimmunoglobulinemias | Paraimmunoglobulinemia | Plasma Cell Dyscrasias | Cell Dyscrasia, Plasma | Cell Dyscrasias, Plasma | Dyscrasia, Plasma Cell | Dyscrasias, Plasma Cell | Plasma Cell Dyscrasia | Gammopathy, Monoclonal | Gammopathies, Monoclonal | Monoclonal Gammopathy | Monoclonal Gammopathies | Gammapathy, Monoclonal | Gammapathies, Monoclonal | Monoclonal Gammapathy | Monoclonal Gammapathies
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00041Adalimumab--
BADD_D00367Carfilzomib0.000627%
BADD_D01223Ixazomib0.000112%
BADD_D01253Lenalidomide0.000964%
BADD_D01567Nilotinib--
BADD_D01798Pomalidomide0.000530%
BADD_D02192Thalidomide0.000530%
BADD_D02464Fingolimod0.000241%
The 1th Page    1    Total 1 Pages